What is Gossamer Bio?
Gossamer Bio is a clinical-stage biopharmaceutical enterprise dedicated to the discovery, acquisition, development, and commercialization of novel therapeutics. The company's strategic focus areas encompass the critical disease domains of immunology, inflammation, and oncology. Headquartered in San Diego, California, Gossamer Bio aims to address unmet medical needs through innovative drug development.
How much funding has Gossamer Bio raised?
Gossamer Bio has raised a total of $332M across 2 funding rounds:
Share Placement
$120M
Share Placement
$212M
Share Placement (2022): $120M, investors not publicly disclosed
Share Placement (2023): $212M led by New Enterprise Associates, EcoR1 Capital, Armistice Capital, and Madison Avenue Partners
Key Investors in Gossamer Bio
New Enterprise Associates
New Enterprise Associates (NEA) is a venture capital firm established in 1977, focused on helping entrepreneurs build businesses. They are known for their significant investments across various stages of company development.
EcoR1 Capital
EcoR1 Capital is a San Francisco-based investment fund specializing in the biotech sector, aiming to foster long-term partnerships with innovative entrepreneurs advancing therapeutic innovation and developing new medicines.
Armistice Capital
Armistice Capital is a global hedge fund employing a value-oriented and event-driven investment strategy, primarily targeting the health care and consumer sectors for strategic investments.
What's next for Gossamer Bio?
The recent major enterprise-level funding positions Gossamer Bio for accelerated growth and the advancement of its therapeutic candidates through critical clinical milestones. This strategic capital infusion is expected to bolster research and development efforts, potentially enabling the company to expand its pipeline and pursue new strategic partnerships. The company's trajectory suggests a focus on scaling operations and progressing its portfolio towards commercialization.
See full Gossamer Bio company page
